Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Android fat distribution

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Android fat distribution. Displaying page 1 of 1.
    EudraCT Number: 2013-003862-15 Sponsor Protocol Number: 2013-601 Start Date*: 2013-11-19
    Sponsor Name:Jens Faber
    Full Title: Liraglutide in Polycystic Ovary Syndrome A randomised, double-blind, placebo-controlled study of the effect of Liraglutide in Polycystic ovary syndrome on risk markers of vascular Thrombosis
    Medical condition: Polycystic Ovary Syndrome (PCOS), especialy signs of early cardiovascular disease in women with PCOS.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-001711-30 Sponsor Protocol Number: RIMON_R_00961 Start Date*: 2006-10-11
    Sponsor Name:sanofi aventis Groupe
    Full Title: A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fast...
    Medical condition: abdominally obese patients with impaired fasting blood glucose with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) CZ (Completed) SI (Completed) FR (Completed) NL (Prematurely Ended) NO (Completed) FI (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) LT (Prematurely Ended) HU (Completed) SK (Completed) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001716-71 Sponsor Protocol Number: RIMON_C_01346 Start Date*: 2006-09-12
    Sponsor Name:sanofi aventis Groupe
    Full Title: A RANDOMIZED, DOUBLE BLIND, TWO ARM, PARALLEL, PLACEBO CONTROLLED STUDY OF RIMONABANT 20MG EFFECT ON HIGH DENSITY LIPOPROTEIN KINETICS IN PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABO...
    Medical condition: PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABOLIC RISK FACTORS
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002077-31 Sponsor Protocol Number: RIMON_L_01814 Start Date*: 2008-09-09
    Sponsor Name:SANOFI-AVENTIS S.P.A
    Full Title: Effects of Rimonabant on urinary albumin excretion rate on the components of the metabolic syndrome in patients with type 2 diabetes mellitus and microalbuminuria on background ramipril treatment. ...
    Medical condition: Abdominal obese patients with type 2 diabetes mellitus and microalbuminuria.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015982-29 Sponsor Protocol Number: UMCU-Vasc-14A Start Date*: 2010-07-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study the effects of aliskiren, hydrochlorothiazide and moxonidine on endothelial dysfunction in obesity related hyper...
    Medical condition: Hypertension in subjects with abdominal obesity and the metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059179 Abdominal obesity LLT
    12.1 10052066 Metabolic syndrome LLT
    12.1 10020772 Hypertension LLT
    12.1 10065941 Central obesity LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009278-29 Sponsor Protocol Number: S51477 Start Date*: Information not available in EudraCT
    Sponsor Name:UZ Leuven
    Full Title: Follow-up studie: Metformin therapie bij kinderen en adolescenten met neurogene of neuromusculaire aandoeningen
    Medical condition: Neuromuscular and neurological diseases, associated with obesity and insulin resistance
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022489 Insulin resistance LLT
    9.1 10022489 Insulin resistance PT
    9.1 10029883 Obesity LLT
    9.1 10065941 Central obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001715-30 Sponsor Protocol Number: RIMON_R_00962 Start Date*: 2006-10-23
    Sponsor Name:sanofi aventis Groupe
    Full Title: A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with...
    Medical condition: abdominally obese patients with dyslipidemia with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) CZ (Completed) SI (Completed) NL (Completed) SE (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) SK (Completed) HU (Completed) GR (Completed) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002568-27 Sponsor Protocol Number: PM-C-0172 Start Date*: 2006-05-08
    Sponsor Name:Sanofi-Synthelabo Groupe
    Full Title: A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with...
    Medical condition: Abdominally obese patients with metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DK (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005779-86 Sponsor Protocol Number: GFT505-208-3 Start Date*: 2008-12-26
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-...
    Medical condition: Atherogenic dyslipidaemic patients with abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058108 Dyslipidaemia LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002951-33 Sponsor Protocol Number: RIMON_L_01031 Start Date*: Information not available in EudraCT
    Sponsor Name:sanofi-aventis, S.A.
    Full Title: A 12-month multicentre, randomised, double-blind, placebo-controlled study with two parallel groups to assess the effects of rimonabant 20 mg in patients with abdominal obesity and microalbuminuria...
    Medical condition: Patients with abdominal obesity, with type 2 diabetes mellitus or dyslipidaemia, with or without other cardiometabolic risk factors.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10059179 Abdominal obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004337-41 Sponsor Protocol Number: GFT505-207-2 Start Date*: 2008-01-11
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-...
    Medical condition: Atherogenic dyslipidaemic patients with abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059179 Abdominal obesity LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023219-32 Sponsor Protocol Number: GFT505-210-6 Start Date*: Information not available in EudraCT
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy of GFT505 (80mg) orally administered once daily for 8 weeks on insulin sensitivity and hepatic glucose production using a glucose clamp technique and Safety i...
    Medical condition: Patients with insulin resistance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036481 Pre-diabetes LLT
    12.1 10059179 Abdominal obesity LLT
    12.1 10022489 Insulin resistance LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-011003-23 Sponsor Protocol Number: GFT505-209-4 Start Date*: 2009-05-28
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double ...
    Medical condition: patients presenting with impaired glucose tolerance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036481 Pre-diabetes LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:22:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA